AstraZeneca Annual Report and Form 20-F Information 2011
AstraZeneca Annual Report and Form 20-F Information 2011
AstraZeneca Annual Report and Form 20-F Information 2011
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
China: We announcedour decision to invest$<strong>20</strong>0 million in amanufacturing facility inTaizhou, Jiangsu province<strong>and</strong> our agreement toacquire GuangdongBeiKang PharmaceuticalCompany Limited.9,600Aroundemployees work at our 23 Supply <strong>and</strong>Manufacturing sites in 16 countries.11,300Aroundemployees work in our R&D organisation<strong>and</strong> we have 14 principal R&D centresin eight countries.Regional salesEstablished ROW$5,901m(+4%)Our top 10 medicines by sales valuein <strong>20</strong>11 were:CardiovascularCrestorfor managing cholesterol levelsSeloken/Toprol-XLfor hypertension, heart failure<strong>and</strong> anginaAtac<strong>and</strong>for hypertension <strong>and</strong> heart failureGastrointestinalNexiumfor acid-refluxLosec/Prilosecfor the treatment of acid relateddiseasesInfectionSynagisfor RSV, a respiratory infectionin infantsNeuroscienceSeroquel IRfor schizophrenia <strong>and</strong> bipolardisorderSeroquel XRfor schizophrenia, bipolar disorder<strong>and</strong> major depressive disorderOncologyZoladexfor prostate <strong>and</strong> breast cancerRespiratory & InflammationSymbicortfor asthma <strong>and</strong> chronicobstructive pulmonary diseaseOur activities touch many people’s lives<strong>and</strong> we are committed to working in aspirit of collaboration to achieve ourgoal of better health for patients:> For patients <strong>and</strong> physicians, we provide medicines forsome of the world’s most serious diseases.> For the people who pay for healthcare, we work to makesure that our medicines offer real value for money.> For our employees, we provide a culture in whichthey can feel appreciated, energised <strong>and</strong> rewardedfor their contribution.> For our shareholders, we aim to deliver value throughour continued focus on innovation <strong>and</strong> running ourbusiness efficiently.> For the wider community, we want to be valued for thecontribution our medicines make to society <strong>and</strong> trustedfor the way in which we do business.We work closely with all our stakeholders to underst<strong>and</strong>their challenges <strong>and</strong> how we can combine our skills <strong>and</strong>resources to achieve a common goal: improved health.Overview<strong>AstraZeneca</strong> <strong>Annual</strong> <strong>Report</strong> <strong>and</strong> <strong>Form</strong> <strong>20</strong>-F <strong>Information</strong> <strong>20</strong>11 <strong>AstraZeneca</strong> at a glance 3
Change language